New research provides hope for childhood cancer sufferers

July 20, 2007

Dr Richard Lock, Head of the Leukaemia Biology Program at the Children’s Cancer Institute Australia for Medical Research, Sydney, along with collaborators from the Childrens Hospital Los Angeles and University of Southern California, USA, recently published their findings in the prestigious scientific journal Blood.

ALL is the most common form of childhood cancer. Over the years, improvements in primary therapy have increased the cure rate to approximately 80 percent. However, for the 20 percent of patients who relapse, the majority will die.

“When used in combination with common drugs administered in ALL therapy, ABT-737 has the ability to enhance the combined toxicity of these drugs against the leukaemia cells with minimal effects on the normal cells of the body,” said Dr Lock.

Resistance to common therapeutic drugs is associated with poor long-term outcomes in leukaemia patients. In the study, the effects of ABT-737 in combination with three common chemotherapeutic agents: L-Asparaginase, vincristine and dexamethasone, were tested on a number of ALL cell lines under conditions which were considered clinically relevant for the disease.

ABT-737, developed by Abbott Laboratories, acts by inhibiting the Bcl-2 family of proteins. These proteins are expressed in ALL and inhibit the mechanisms responsible for destroying leukaemia cells. High levels of expression of Bcl-2 is linked with chemoresistance in a variety of cancers.

“There is a critical need for new drugs with novel mechanisms of action that might improve the outcome for relapsed ALL patients,” said Dr Lock.

Source: Research Australia

Explore further: New drug combination shows promise in tackling leukaemia treatment resistance

Related Stories

New drug hope for babies with leukaemia

October 12, 2016

Telethon Kids Institute (TKI) researchers have discovered a new drug combination to help babies battle a rare, aggressive type of leukaemia with grim cure rates.

Report shows neglected cancer is killing the young

October 11, 2016

A report published today, 11th October 2016, by charity Brain Tumour Research shows that funding for research into brain tumours is still woefully inadequate, despite it being the biggest cancer killer of children and people ...

Leukaemia blood testing has 'massive potential'

August 17, 2016

Researchers at The University of Manchester have unlocked the potential of a new test which could revolutionise the way doctors diagnose and monitor a common childhood Leukaemia.

Recommended for you

Fighting cancer with the power of immunity

October 24, 2016

Harnessing the body's own immune system to destroy tumors is a tantalizing prospect that has yet to realize its full potential. However, a new advance from MIT may bring this strategy, known as cancer immunotherapy, closer ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.